

**Session Title:** #110: Use of Induction Chemotherapy in Clinical Practice

**Session Type:** Education Session

**Date:** Friday, June 4

**Location:** S406 (Vista Room)

**Time:** 1:00 PM - 2:15 PM

- Combined Modality Therapy in Perspective

*Everett E. Vokes, MD*

- Induction Chemotherapy and Sequential Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck in Clinical Practice

*Marshall R. Posner, MD*

- Radiation oncology perspective. Dr. Beitler is at Emory University Winship Cancer Institute in Atlanta GA.

*Jonathan Jay Beitler, MD, MBA, FACR*

---

**Session Title:** #182: Head and Neck Cancer

**Session Type:** Poster Discussion Session

**Date:** Friday, June 4

**Location:** S403

**Time:** 2:00 PM - 6:00 PM

- Head and Neck Cancer

*Cherie-Ann Nathan, MD*

- Head and Neck Cancer

*Ranee Mehra, MD*

1 #5512-Long-term results from TAX324: A phase III trial of sequential therapy comparing TPF to PF in locally advanced (LA) squamous cell cancer of the head and neck (HNC).

*Jochen H. Lorch*

2 #5513-Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303).

*Harold J. Wanebo*

3 #5514-TPF induction-radioimmunochemotherapy for the treatment of advanced head and neck cancer.

*Wolf-Oliver Jordan*

4 #5515-Induction docetaxel, cisplatin, and cetuximab (TPE) followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer (HNC): Mature results with HPV analysis.

*Robert L. Ferris*

5 #5516-Radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma: Ten-year results of the 94-01 GORTEC randomized study.

*Gilles Calais*

6 #5517-Need for postradiotherapy neck dissection by tumor site and nodal stage for head and neck cancer.

*Juliette Thariat*

7 #5518-Clinical efficacy and tolerability of continuous course reirradiation with concurrent weekly carboplatin-paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head and neck (SCCHN).

*Anjali Marwaha*

- Discussion

*Danny Rischin, MD*

9 #5520-Use of XPF expression in tumors and XPF single nucleotide polymorphisms to predict clinical outcome in head and neck cancer.

*Alec E. Vaezi, MD, PhD*

10 #5521-Gene expression profiling of oral preneoplastic lesions (OPL) from a prospective prevention trial.

*Pierre Saintigny*

11 #5522-Comparison of primary site biopsies and transverse surgical sections of squamous cell carcinoma of the head and neck for translational research analysis.

*Markus Hambek*

12 #5523-Association of circulating tumor cells with lymph node metastasis in squamous cell carcinoma of the head and neck region (SCCHN).

*Inge Tinhofer*

13 #5524-Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving induction chemotherapy and definitive chemoradiotherapy.

*Sung-Bae Kim*

- Discussion

*Cherie-Ann Nathan, MD*

14 #5525-Oropharynx cancer (OPC) in TAX 324: Human papillomavirus (HPV) and survival.

*Marshall R. Posner, MD*

15 #5526-A population-based evaluation of incidence trends in oropharynx cancer (OP) focusing on socioeconomic status (SES), sex, and race/ethnicity.

*A. Dimitrios Colevas, MD*

16 #5527-Human papillomavirus (HPV) transmission from oropharyngeal cancer patients to sexual partners.

*Vassiliki Papadimitrakopoulou*

17 #5528-Relationship between epidermal growth factor receptor (EGFR) gene copy number, p16 status, and outcome in locally advanced squamous cell carcinoma of the head and neck (LASCCHN).

*Benjamin J. Solomon*

18 #5529-Plasma human papillomavirus (HPV) DNA as a potential tool for tumor detection and monitoring response in HPV-related oropharyngeal carcinoma (OP).

*Hongbin Cao*

- Discussion

*Anil Chaturvedi, DVM, PhD*

19 #5530-An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study.

*K. Govind Babu*

20 #5531-Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

*Christophe Le Tourneau, MD, PhD*

21 #5532-A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN).

*Anita Lynn Sabichi, MD*

22 #5533-Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results and correlation with TS, MTHFR, and VEGF gene polymorphisms.

*Athanassios Argiris*

23 #5534-Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial.

*Ricard Mesia*

24 #5535-Chemoprevention with erlotinib and celecoxib in advanced premalignant lesions of the head and neck: Results of a phase I study.

*Nabil F. Saba*

25 #5536-Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements.

*Amy S. Lucas*

- Discussion

*Ranee Mehra, MD*

---

**Session Title:** #249: Head and Neck Cancer

**Session Type:** Poster Discussion Session

**Date:** Friday, June 4

**Location:** S406 (Vista Room)

**Time:** 5:00 PM - 6:00 PM

- Head and Neck Cancer

*Cherie-Ann Nathan, MD*

- Head and Neck Cancer

*Ranee Mehra, MD*

1 #5512-Long-term results from TAX324: A phase III trial of sequential therapy comparing TPF to PF in locally advanced (LA) squamous cell cancer of the head and neck (HNC).

*Jochen H. Lorch*

2 #5513-Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303).

*Harold J. Wanebo*

3 #5514-TPF induction-radioimmunochemotherapy for the treatment of advanced head and neck cancer.

*Wolf-Oliver Jordan*

4 #5515-Induction docetaxel, cisplatin, and cetuximab (TPE) followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer (HNC): Mature results with HPV analysis.

*Robert L. Ferris*

5 #5516-Radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma: Ten-year results of the 94-01 GORTEC randomized study.

*Gilles Calais*

6 #5517-Need for postradiotherapy neck dissection by tumor site and nodal stage for head and neck cancer.

*Juliette Thariat*

7 #5518-Clinical efficacy and tolerability of continuous course reirradiation with concurrent weekly carboplatin-paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head and neck (SCCHN).

*Anjali Marwaha*

- Discussion

*Danny Rischin, MD*

9 #5520-Use of XPF expression in tumors and XPF single nucleotide polymorphisms to predict clinical outcome in head and neck cancer.

*Alec E. Vaezi, MD, PhD*

10 #5521-Gene expression profiling of oral preneoplastic lesions (OPL) from a prospective prevention trial.

*Pierre Saintigny*

11 #5522-Comparison of primary site biopsies and transverse surgical sections of squamous cell carcinoma of the head and neck for translational research analysis.

*Markus Hambek*

12 #5523-Association of circulating tumor cells with lymph node metastasis in squamous cell carcinoma of the head and neck region (SCCHN).

*Inge Tinhofer*

13 #5524-Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving induction chemotherapy and definitive chemoradiotherapy.

*Sung-Bae Kim*

- Discussion

*Cherie-Ann Nathan, MD*

14 #5525-Oropharynx cancer (OPC) in TAX 324: Human papillomavirus (HPV) and survival.

*Marshall R. Posner, MD*

15 #5526-A population-based evaluation of incidence trends in oropharynx cancer (OP) focusing on socioeconomic status (SES), sex, and race/ethnicity.

*A. Dimitrios Colevas, MD*

16 #5527-Human papillomavirus (HPV) transmission from oropharyngeal cancer patients to sexual partners.

*Vassiliki Papadimitrakopoulou*

17 #5528-Relationship between epidermal growth factor receptor (EGFR) gene copy number, p16 status, and outcome in locally advanced squamous cell carcinoma of the head and neck (LASCCHN).

*Benjamin J. Solomon*

18 #5529-Plasma human papillomavirus (HPV) DNA as a potential tool for tumor detection and monitoring response in HPV-related oropharyngeal carcinoma (OP).

*Hongbin Cao*

- Discussion

*Anil Chaturvedi, DVM, PhD*

19 #5530-An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study.

*K. Govind Babu*

20 #5531-Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

*Christophe Le Tourneau, MD, PhD*

21 #5532-A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN).

*Anita Lynn Sabichi, MD*

22 #5533-Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results and correlation with TS, MTHFR, and VEGF gene polymorphisms.

*Athanassios Argiris*

23 #5534-Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial.

*Ricard Mesia*

24 #5535-Chemoprevention with erlotinib and celecoxib in advanced premalignant lesions of the head and neck: Results of a phase I study.

*Nabil F. Saba*

25 #5536-Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements.

*Amy S. Lucas*

- Discussion

*Ranee Mehra, MD*

---

**Session Title:** #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

**Session Type:** Special Session

**Date:** Saturday, June 5

**Location:** N Hall B1

**Time:** 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

*Daniel D. Von Hoff, MD*

---

**Session Title:** #167: Highlights of the Day I including Clinical Trials Participation Awards

**Session Type:** Highlights of the Day

**Date:** Sunday, June 6

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

*Everett E. Vokes, MD*

- Clinical Trials Participation Awards

*Douglas W. Blayney, MD*

- Discussion: Lymphoma and Plasma Cell Disorders  
*Bruce D. Cheson, MD*
  - Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy  
*Alan B Sandler, MD*
  - Discussion: Patient and Survivor Care  
*Gretchen Genevieve Kimmick, MD*
  - Discussion: Melanoma/Skin Cancers  
*F. Stephen Hodi, MD*
- 

**Session Title:** #56: HPV Status and Clinical Decision-making for Patients with Oropharynx Cancer

**Session Type:** Education Session

**Date:** Sunday, June 6

**Location:** E Hall D2

**Time:** 8:00 AM - 9:15 AM

- Clinical Implications of Human Papillomavirus-etiology of Head and Neck Cancers: An Update  
*Maura L. Gillison, MD, PhD*
  - The Development of Prospective HPV-specific Head and Neck Cancer Clinical Trials  
*Andy Trotti, MD*
  - Biological Correlates of HPV Tumor Status  
*Lisa F. Licitra, MD*
- 

**Session Title:** #203: Head and Neck Cancer

**Session Type:** General Poster Session

**Date:** Sunday, June 6

**Location:** S Hall A2

**Time:** 8:00 AM - 12:00 PM

10A #5537-Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303).

*Ann Marie Egloff*

10B #5538-Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (HNSCC) using AQUA.

*Eirini Pectasides*

10C #5539-Analysis of ERCC1 (excision repair cross complementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297.

*Ranee Mehra, MD*

10D #5540-ERCC1 protein, mRNA expression, and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma (HNSCC) patients treated with surgery and adjuvant cisplatin-based chemoradiation (CRT).

*Gilberto Castro*

10E #5541-Expression and prognostic significance of x-ray crosscomplementation group 1 (XRCC1) in head and neck squamous cell carcinoma patients undergoing concurrent chemoradiation.

*Mei-Kim Ang*

10F #5542-Use of angiopoietin-1 expression in squamous cell carcinoma of the head and neck to predict disease-free survival.

*Muthuswamy Dhiwakar*

10G #5543-Correlation of expression of haptoglobin and recurrence in head and neck squamous cell cancer.

*Yu-Chieh Su, MD, MSc*

10H #5544-Outcomes in HPV-associated oropharyngeal squamous cell carcinoma after postoperative or definitive nonsurgical therapy.

*Christopher R. Spencer*

11A #5545-Detection of antibodies to the HPV16 proteome in head and neck cancer patient sera.

*Karen S. Anderson*

11B #5546-Prognosis of HPV-positive squamous cell carcinoma of tonsil-expressing high level of p16 and low level of EGFR.

*Hye Sung Won*

11F #5547-Use of T-cell infiltrate to predict long-term survival following local therapy in tongue cancer patients.

*Jung Sun Kim, BM, BCh, MSc*

11G #5548-Prognostic value of biomarkers in tissue microarrays (TMAs) of squamous cell carcinomas of the oral tongue (SCCOT).

*William Nassib William Junior*

11H #5549-Evaluation of ALDH1-A1 as a biomarker for metastasis of head and neck cancer.

*Zhuo Georgia Chen*

12A #5550-The prognostic value of STAT3 protein in patients with head and neck squamous cell carcinoma (HNSCC) harboring PTEN loss.

*George Fountzilas*

12B #5551-Expression of drug-resistance-related proteins in nasopharyngeal cancer (NPC) patients treated with cisplatin-based concurrent chemoradiotherapy.

*Hyun Woo Lee, MD*

12F #5552-Association of high Gli1 expression with poor survival in head and neck cancer patients treated with radiation therapy (RTOG 9003).

*Christine H. Chung*

12G #5553-Prospective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).

*Jessica Ley*

12H #5554-A phase II study of pemetrexed (P) plus gemcitabine (G) in patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).

*David G. Pfister*

13A #5555-A phase II trial of biweekly gemcitabine and paclitaxel (GEMTAX) combination in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group study.

*Kathleen Elizabeth Bickel*

13B #5556-A phase II study of GW786034 (pazopanib) in Asian patients with recurrent/metastatic undifferentiated nasopharyngeal carcinoma.

*Wan Teck Lim*

13C #5557-Efficacy of combining targeted therapies cetuximab and dasatinib for resistant salivary gland carcinomas in vitro.

*Andrew Brohl*

13D #5558-Combined hedgehog and epidermal growth factor receptor (EGFR) inhibition in a direct patient tumor model (DPTM) of head and neck squamous cell cancer (HNSCC).

*Stephen B Keysar, PhD*

13E #5559-Activity of novel RET inhibitors against RET genotypes associated with medullary thyroid cancer.

*Ann Gramza*

13F #5560-Mature results of a phase I trial of bortezomib, cisplatin, and radiotherapy for advanced or recurrent head and neck cancer.

*Rita Susan Axelrod*

13G #5561-Phase I trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.

*Johnny Kao*

13H #5562-HN5: A phase I/II study of erlotinib as adjuvant therapy in patients treated by chemoradiation therapy (CRT) for locally advanced SCCHN.

*Denis Soulieres*

14A #5563-The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LAHNC): Preliminary toxicity report.

*Robert I. Haddad*

14B #5564-Interim safety analysis of a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-) paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in patients with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC).

*Brian Andrew Van Tine*

14C #5565-Results from a pilot study of nimotuzumab with concurrent chemoradiation in patients with locally advanced squamous cell carcinoma of head and neck.

*Madhur Gupta*

14D #5566-Hyperfractionated radiation therapy and concurrent chemotherapy for advanced head and neck cancer.

*Khaled Ahmed AL Saleh*

14E #5567-Concurrent chemoradiation in stage II laryngeal carcinomas.

*Rejiv Rajendranath*

14F #5568-Network meta-analysis (MA) of taxane-based neoadjuvant chemotherapy (NCT) for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

*John Paul McGhie*

14G #5569-Induction chemotherapy with carboplatin and paclitaxel followed by radiotherapy and concurrent weekly carboplatin plus paclitaxel in locally advanced nasopharyngeal carcinoma in a nonendemic population.

*Gianmauro Numico*

14H #5570-Phase II study of synchronous chemoradiotherapy with capecitabine in patients with locally advanced squamous cell carcinoma of the head and neck.

*Apurna Jegannathen*

15A #5571-Organ preservation using carboplatin, capecitabine, docetaxel, and radiotherapy in head and neck cancer: A phase II study.

*Daniel F. Saragiotto*

15B #5572-Prediction of outcome of TPF with or without cetuximab induction chemotherapy in head and neck squamous cell carcinoma (HNSCC) using the FLAVINO assay.

*Andreas Dietz*

15C #5573-The persistence of symptom burden after radiation treatment for head and neck cancer (HNC).

*David Ira Rosenthal*

15D #5574-Oncologically endoscopic nasopharyngectomy for T1/T2a and selected T2b/T3 nasopharyngeal malignancies with nasopharynx resurfaced with posterior pedicle nasal mucoperiosteum flap.

*Ming-Yuan Chen*

15E #5575-A comparison between surgery plus radiotherapy and exclusive chemoradiation therapy regimes in oral and oropharyngeal cancer: Long-term functional and psychological impact.

*Mario Airoidi*

15F #5576-Chemotherapy-enhanced accelerated radiotherapy for intermediate-volume hypopharyngeal cancer.

*Mitsuhiko Kawashima*

15G #5577-An open, multicenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma (NPC): Preliminary report.

*Tai-xiang Lu, Prof., Dr.*

15H #5578-Competing mortality in advanced head and neck cancer: A population-based study.

*Brent Shane Rose*

16A #5579-Functional outcomes after cisplatin (C)-based concurrent chemoradiation (CCRT) in patients (pts) with human papillomavirus (HPV)-related squamous cell carcinoma of the oropharynx (SCCOP).

*Cristina P. Rodriguez*

16B #5580-Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): Preliminary toxicity results.

*David N. Hayes*

16C #5581-Toxicity and one-year tumor control with induction chemotherapy and bioradiotherapy for locally advanced unresectable head and neck cancer.

*Clas Mercke*

16D #5582-Long-term treatment outcome of nasopharyngeal carcinoma (NPC) using intensity-modulated radiotherapy (IMRT).

*Michael K. Kam*

16E #5583-Postoperative adjuvant chemoradiotherapy versus radiotherapy alone for head and neck squamous cell carcinoma: A meta-analysis evaluating the role of chemotherapy schedules.

*Gustavo A Viani*

16F #5584-Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): First overview of complete data set.

*Paul M. Harari*

16G #5585-Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): Findings related to the oropharynx.

*Stuart J. Wong*

16H #5586-Phase I trial of combination sorafenib and tipifarnib: The experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC).

*Maria E. Cabanillas*

17A #5587-A phase II study of VEGF trap (afibercept) in patients with radioactive iodine-refractory, positron emission tomography (PET) positive thyroid carcinoma.

*Eric Jeffrey Sherman*

17B #5588-Epidemiology, treatment outcome, and survival of anaplastic thyroid cancer (ATC) in the United States: A period prevalence SEER database study 1973-2006.

*Akm Mosharraf Hossain*

17C #5589-Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer.

*R. Donald Harvey*

17D #5590-Sorafenib in patients (pts) with advanced thyroid carcinoma (TC): A compassionate use program.

*Jaume Capdevila*

17E #5591-Intensity-modulated radiation therapy combined with concurrent and adjuvant chemotherapy in anaplastic thyroid carcinoma: A single-institution study.

*Keith Christopher Bible*

17F #5592-Use of cystatin C as a biomarker for glomerular filtration rate in patients with head and neck cancer receiving cisplatin-based chemotherapy.

*Edwin Boelke*

17G #5593-Effects of aprepitant use in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with high-dose cisplatin and radiation (RT).

*Michael Ong, MD, FRCPC*

17H #5594-Prognostic significance of epithelitis by concurrent cetuximab and radiotherapy (RT) for locally advanced head and neck squamous cell carcinoma (HNSCC) patients (Pts).

*Juan J. Grau*

18A #5595-Economic burden of resected squamous cell carcinoma of the head and neck (SCCHN) in a U.S. managed care population.

*Benjamin Chastek*

18B #5596-Survival from head and neck cancers based on socioeconomic status in Asians.

*Karen P. M. Chu*

18C #5597-Stress and depression in head and neck cancer patients by primary surgery versus primary radiotherapy treatment modality.

*Courtney Ann Jensen*

18D #5598-Comparison of quality of lives between voice-rehabilitated and nonrehabilitated laryngectomees in a developing world community.

*Bipin Thomas Varghese*

18E #5599-Do the treatment outcome priorities of head and neck cancer patients change after undergoing radiation treatment?

*Hoda Badr*

18F #5600-The relationship of presenting symptom burden and survival in patients with head and neck cancer (HNC).

*Gary Brandon Gunn*

18G #5601-Routine versus clinically indicated post-treatment surveillance in head and neck cancer.

*Neil M. Iyengar, MD*

**Session Title:** #140: Therapeutic Choices for Patients with Intermediate-stage Head and Neck Cancer

**Session Type:** Clinical Problems in Oncology Session

**Date:** Sunday, June 6

**Location:** E451a

**Time:** 9:45 AM - 11:00 AM

- Management Strategies for Intermediate Stage Larynx Cancer  
*Merrill S. Kies, MD*
- Multidisciplinary Treatment of Intermediate Stage Oral Cavity Cancer  
*Ted Teknos, MD*
- Intermediate Stage Oropharyngeal Cancer  
*Christopher Nutting, MD*

**Session Title:** #143: Plenary Session including Science of Oncology Award and Lecture

**Session Type:** Plenary Session

**Date:** Sunday, June 6

**Location:** N Hall B1

**Time:** 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture  
*Douglas W. Blayney, MD*
- Plenary Session including Science of Oncology Award and Lecture  
*Daniel F. Hayes, MD*
- Plenary Session including Science of Oncology Award and Lecture  
*Frank McCormick, PhD, FRS*
- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.  
  
*Robert A Burger*
- Discussion  
*Elizabeth A. Eisenhauer, MD*
- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

- Discussion

*Martin J. Edelman, MD*

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

*Steven O'Day, MD*

- Discussion: Ipilimumab: The light at the end of the tunnel?

*Vernon K Sondak, MD*

---

**Session Title:** #168: Highlights of the Day II including Partners in Progress Award

**Session Type:** Highlights of the Day

**Date:** Monday, June 7

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

*Douglas W. Blayney, MD*

- Highlights of the Day II including Partners in Progress Award

*Kim Allyson Margolin, MD*

- Partners in Progress Award Recipient

*Ellen V. Sigal, PhD*

- Discussion: Genitourinary (Prostate) Cancer

*Nicholas J. Vogelzang, MD*

- Discussion: Gastrointestinal (Colorectal) Cancer

*Howard S. Hochster, MD*

- Discussion: Gynecologic Cancer

*Claire F. Verschraegen, MD*

- Discussion: Myeloma

*Jean L. Harousseau, MD*

- Discussion: Cancer Prevention/Epidemiology

*Scott Michael Lippman, MD*

**Session Title:** #77: Neoadjuvant versus Adjuvant Chemotherapy and Radiation for Esophagogastric Cancers: Do the Results of Recent Trials Give Us a Direction?

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E Hall D2

**Time:** 9:45 AM - 11:00 AM

- (Neo)adjuvant chemotherapy in the management of localized esophagogastric carcinoma.

*Peter C. Enzinger, MD*

- Neoadjuvant chemoradiation in the management of localized esophagogastric carcinoma.

*Mohan Suntharalingam, MD*

- Implications for surgery following chemotherapy or chemoradiation.

*Cliff P. Connery, MD*

**Session Title:** #226: Promising Targeted Therapies for Head and Neck Cancer

**Session Type:** Clinical Science Symposium

**Date:** Monday, June 7

**Location:** E354a

**Time:** 9:45 AM - 11:15 AM

- Promising Targeted Therapies for Head and Neck Cancer

*Bonnie S. Glisson, MD*

- #5500-Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02.

*Sandra Schmitz, MD*

- Discussion

*Bonnie S. Glisson, MD*

- #5501-BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study.

*Tanguy Y. Seiwert, MD*

- #5502-Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET.

**Session Title:** #133: Management of Less Common Head and Neck Cancers

**Session Type:** Clinical Problems in Oncology Session

**Date:** Monday, June 7

**Location:** E451a

**Time:** 11:30 AM - 12:45 PM

- Salivary gland cancer  
*David J. Adelstein, MD*
- Nasopharyngeal carcinoma  
*Quynh-thu Le, MD*
- Cutaneous melanoma of the head and neck  
*Carol Rossier Bradford, MD*

**Session Title:** #155: Head and Neck Cancer

**Session Type:** Oral Abstract Session

**Date:** Monday, June 7

**Location:** E354b

**Time:** 3:00 PM - 6:00 PM

- Head and Neck Cancer  
*Søren M. Bentzen, PhD, DSC*
- Head and Neck Cancer  
*A. Dimitrios Colevas, MD*
- #5503-Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA).  
  
*Samuel A. Wells*
- #5504-Phase II trial of sunitinib in medullary thyroid cancer (MTC).  
*Jonas A. De Souza, MD*
- #5505-Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN).  
*Kevin J Harrington*
- #LBA5506-An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with non-curable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy

- Discussion

*A. Dimitrios Colevas, MD*

- #5507-A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome.

*K. Kian Ang*

- #5508-Postoperative accelerated radiotherapy (POPART) versus conventional postoperative radiotherapy (CPORT) in squamous cell head and neck cancer: A multicenter prospective randomized study of the Dutch Head and Neck Cooperative Study Group.

*Johannes A. Langendijk*

- Discussion

*Søren M. Bentzen, PhD, DSC*

- #5509-Prognostic significance of interleukin-8 (IL-8) and hepatocyte growth factor (HGF) in patients with head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on a phase III trial.

*Danny Rischin, MD*

- #5510-Analysis of the effect of p16 and tobacco pack-years (p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in Radiation Therapy Oncology Group (RTOG) protocol 9003.

*Maura L. Gillison, MD, PhD*

- #5519-PTEN as prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck.

*Mirosław P Snietura, MD*

- Discussion

*Ezra E. W. Cohen, MD, FRCPC*

---

**Session Title:** #169: Highlights of the Day III

**Session Type:** Highlights of the Day

**Date:** Tuesday, June 8

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day III

*Kathy Miller, MD*

- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy

*Kathy Miller, MD*

- Discussion: Lung Cancer - Metastatic  
*Charles M. Rudin, MD, PhD*
- Discussion: Sarcoma  
*Gary K. Schwartz, MD*
- Discussion: Gastrointestinal (Noncolorectal) Cancer  
*C. D. Blanke, MD*
- Discussion: Head and Neck Cancer  
*Everett E. Vokes, MD*